Clinical trial to evaluate the efficacy of pyrepemat on the frequency of falls in patients with Parkinson's disease

THE STUDY IS BEING CONDUCTED FOR RESEARCH PURPOSES TO TEST THE STUDY DRUG, PIREPEMAT, FOR THE TREATMENT OF PARKINSON'S DISEASE (PD). THE OBJECTIVE OF THE STUDY IS TO LEARN MORE ABOUT THE EFFICACY AND SAFETY OF PIREPEMAT FOR THE TREATMENT OF PARKINSON'S DISEASE. IN THIS STUDY, PIREPEMAT WILL BE ADMINISTERED IN ADDITION TO THE PATIENT'S USUAL PD MEDICATION. TWO DIFFERENT DAILY DOSES OF THE STUDY DRUG, PIREPEMAT, WILL BE COMPARED TO A PLACEBO. A PLACEBO IS A TREATMENT/TABLET THAT LOOKS/TASTS EXACTLY THE SAME AS THE STUDY DRUG, BUT CONTAINS NO ACTIVE INGREDIENTS. YOU WILL RANDOMLY (RANDOMLY, LIKE SPINNING A ROULETTE WHEEL WITH 3 SEGMENTS) DECIDE WHETHER YOU RECEIVE THE STUDY DRUG OR THE PLACEBO. IN THIS STUDY, 1 OUT OF 3 PATIENTS (33%) WILL RECEIVE THE LOW DOSE OF PYREPEMAT (100 MG, 3 TIMES DAILY); 1 OUT OF 3 PATIENTS (33%) WILL RECEIVE THE HIGH DOSE OF PYREPEMAT (200 MG, 3 TIMES DAILY); AND 1 OUT OF 3 PATIENTS (33%) WILL RECEIVE THE PLACEBO. ALL PATIENTS WILL RECEIVE HALF OF THE ASSIGNED STUDY DOSE DURING THE FIRST WEEK OF TREATMENT, BEFORE INCREASING THE DOSE TO THE FULL DOSE STARTING IN THE SECOND WEEK. TO KEEP THE STUDY FAIR, THE STUDY CAREGIVER AND STUDY DOCTOR WILL NOT BE TOLD WHICH STUDY DRUG AND DOSE EACH PATIENT WILL RECEIVE. THIS IS CALLED "BLINDING". IN CASE OF AN EMERGENCY, THE STUDY DOCTOR WILL BE ABLE TO CONSULT THE ASSIGNED TREATMENT AT ANY TIME.